BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kranzler HR, Wesson DR, Billot L. Naltrexone Depot for Treatment of Alcohol Dependence: A Multicenter, Randomized, Placebo-Controlled Clinical Trial: . Alcoholism: Clinical & Experimental Research 2004;28:1051-9. [DOI: 10.1097/01.alc.0000130804.08397.29] [Cited by in Crossref: 111] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 2007;61:4-12. [PMID: 16533497 DOI: 10.1016/j.biopsych.2006.01.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
2 Mannelli P, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil 2011;2011:113-23. [PMID: 21731898 DOI: 10.2147/SAR.S15853] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
3 Farren CK, Scimeca M, Wu R, Malley SO. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 2009;99:317-21. [PMID: 18644685 DOI: 10.1016/j.drugalcdep.2008.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
4 Marcus DJ, Henderson-Redmond AN, Gonek M, Zee ML, Farnsworth JC, Amin RA, Andrews MJ, Davis BJ, Mackie K, Morgan DJ. Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption. PLoS One 2017;12:e0174826. [PMID: 28426670 DOI: 10.1371/journal.pone.0174826] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
5 Perepletchikova F, Krystal JH, Kaufman J. Practitioner review: adolescent alcohol use disorders: assessment and treatment issues. J Child Psychol Psychiatry 2008;49:1131-54. [PMID: 19017028 DOI: 10.1111/j.1469-7610.2008.01934.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
6 Ahmed R, Kotapati VP, Khan AM, Hussain N, Hussain M, Dar S, Kumar J, Begum GA, Esang M, Brainch N, Ahmed S. Adding Psychotherapy to the Naltrexone Treatment of Alcohol Use Disorder: Meta-analytic Review. Cureus 2018;10:e3107. [PMID: 30338182 DOI: 10.7759/cureus.3107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Ober AJ, Watkins KE, Hunter SB, Ewing B, Lamp K, Lind M, Becker K, Heinzerling K, Osilla KC, Diamant AL, Setodji CM. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study. BMC Fam Pract 2017;18:107. [PMID: 29268702 DOI: 10.1186/s12875-017-0673-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
8 Ukrainets IV, Tkach AA, Gorokhova OV, Turov AV, Linsky IV. Studies of 3-O-acyl derivatives of naloxone as its potential prodrugs. Chem Heterocycl Comp 2009;45:405-16. [DOI: 10.1007/s10593-009-0278-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction 2018;113:268-78. [PMID: 28734107 DOI: 10.1111/add.13950] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
10 Liu J, Shi YC, Lee DY. Applications of Pueraria lobata in treating diabetics and reducing alcohol drinking. Chin Herb Med 2019;11:141-9. [PMID: 32831815 DOI: 10.1016/j.chmed.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ober AJ, Watkins KE, Hunter SB, Lamp K, Lind M, Setodji CM. An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol. Implement Sci 2015;10:66. [PMID: 25951953 DOI: 10.1186/s13012-015-0256-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
12 Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210-8. [PMID: 16461865 DOI: 10.1001/archpsyc.63.2.210] [Cited by in Crossref: 221] [Cited by in F6Publishing: 205] [Article Influence: 13.8] [Reference Citation Analysis]
13 Collins SE, Saxon AJ, Duncan MH, Smart BF, Merrill JO, Malone DK, Jackson TR, Clifasefi SL, Joesch J, Ries RK. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial. Contemp Clin Trials 2014;38:221-34. [PMID: 24846619 DOI: 10.1016/j.cct.2014.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 2008;32:1271-83. [PMID: 18482155 DOI: 10.1111/j.1530-0277.2008.00682.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
15 Beatty A, Stock C. Efficacy of long-acting, injectable versus oral naltrexone for preventing admissions for alcohol use disorder. Ment Health Clin 2017;7:106-10. [PMID: 29955507 DOI: 10.9740/mhc.2017.05.106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kunøe N, Opheim A, Solli KK, Gaulen Z, Sharma-Haase K, Latif ZE, Tanum L. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacol Toxicol 2016;17:18. [PMID: 27121539 DOI: 10.1186/s40360-016-0061-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
17 Litten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, Yi HY. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 2013;37:2128-37. [PMID: 23889231 DOI: 10.1111/acer.12197] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
18 Farid WO, Lawrence AJ, Krstew EV, Tait RJ, Hulse GK, Dunlop SA. Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. PLoS One 2012;7:e52812. [PMID: 23300784 DOI: 10.1371/journal.pone.0052812] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
19 Aboujaoude E, Salame WO. Naltrexone: A Pan-Addiction Treatment? CNS Drugs 2016;30:719-33. [PMID: 27401883 DOI: 10.1007/s40263-016-0373-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
20 Raby WN, Carpenter KM, Rothenberg J, Brooks AC, Jiang H, Sullivan M, Bisaga A, Comer S, Nunes EV. Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict 2009;18:301-8. [PMID: 19444734 DOI: 10.1080/10550490902927785] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
21 Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F. Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. BMC Med 2019;17:174. [PMID: 31526369 DOI: 10.1186/s12916-019-1409-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
22 Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv 2019;5:eaax4043. [PMID: 31579824 DOI: 10.1126/sciadv.aax4043] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 16.7] [Reference Citation Analysis]
23 Kunøe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol 2014;77:264-71. [PMID: 23088328 DOI: 10.1111/bcp.12011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
24 Stancil SL, Abdel-Rahman S, Wagner J. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. J Pediatr Pharmacol Ther 2021;26:675-95. [PMID: 34588931 DOI: 10.5863/1551-6776-26.7.675] [Reference Citation Analysis]
25 Niciu MJ, Arias AJ. Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs 2013;27:777-87. [PMID: 23881605 DOI: 10.1007/s40263-013-0096-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
26 Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics 2020;17:55-69. [PMID: 31907876 DOI: 10.1007/s13311-019-00814-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
27 Hegde A, Singh SM, Sarkar S. Long-acting Preparations in Substance Abuse Management: A Review and Update. Indian J Psychol Med 2013;35:10-8. [PMID: 23833336 DOI: 10.4103/0253-7176.112194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Dougherty DM, Karns TE, Mullen J, Liang Y, Lake SL, Roache JD, Hill-Kapturczak N. Transdermal alcohol concentration data collected during a contingency management program to reduce at-risk drinking. Drug Alcohol Depend 2015;148:77-84. [PMID: 25582388 DOI: 10.1016/j.drugalcdep.2014.12.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
29 Abraham AJ, Roman PM. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs 2010;71:460-6. [PMID: 20409441 DOI: 10.15288/jsad.2010.71.460] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
30 Ralevski E, Olivera-Figueroa LA, Petrakis I. PTSD and comorbid AUD: a review of pharmacological and alternative treatment options. Subst Abuse Rehabil 2014;5:25-36. [PMID: 24648794 DOI: 10.2147/SAR.S37399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
31 Henderson-Redmond AN, Guindon J, Morgan DJ. Roles for the endocannabinoid system in ethanol-motivated behavior. Prog Neuropsychopharmacol Biol Psychiatry 2016;65:330-9. [PMID: 26123153 DOI: 10.1016/j.pnpbp.2015.06.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
32 Thakarar K, Weinstein ZM, Walley AY. Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. Postgrad Med J 2016;92:356-63. [PMID: 27004476 DOI: 10.1136/postgradmedj-2015-133720] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
33 Lobmaier PP, Kunøe N, Gossop M, Waal H. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther 2011;17:629-36. [PMID: 21554565 DOI: 10.1111/j.1755-5949.2010.00194.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
34 Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007;2:35. [PMID: 18036213 DOI: 10.1186/1747-597X-2-35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
35 Kim Y, Hack LM, Ahn ES, Kim J. Practical outpatient pharmacotherapy for alcohol use disorder. Drugs Context 2018;7:212308. [PMID: 29445407 DOI: 10.7573/dic.212308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
36 Czoty PW, Stoops WW, Rush CR. Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. Pharmacol Rev 2016;68:533-62. [PMID: 27255266 DOI: 10.1124/pr.115.011668] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
37 Miller PM, Book SW, Stewart SH. Medical treatment of alcohol dependence: a systematic review. Int J Psychiatry Med 2011;42:227-66. [PMID: 22439295 DOI: 10.2190/PM.42.3.b] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
38 Mason BJ, Higley AE. A Translational Approach to Novel Medication Development for Protracted Abstinence. In: Sommer WH, Spanagel R, editors. Behavioral Neurobiology of Alcohol Addiction. Berlin: Springer Berlin Heidelberg; 2013. pp. 647-70. [DOI: 10.1007/978-3-642-28720-6_201] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
39 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
40 Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull 2006;32:644-54. [PMID: 16887890 DOI: 10.1093/schbul/sbl010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
41 Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs. 2013;27:287-299. [PMID: 23456576 DOI: 10.1007/s40263-013-0043-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 6.2] [Reference Citation Analysis]
42 Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008;6:125-50. [PMID: 19305793 DOI: 10.2174/157015908784533842] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
43 Hulse GK. Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol 2013;76:632-41. [PMID: 22946873 DOI: 10.1111/j.1365-2125.2012.04452.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
44 De Sousa A. The pharmacotherapy of alcohol dependence: a state of the art review. Mens Sana Monogr 2010;8:69-82. [PMID: 21327171 DOI: 10.4103/0973-1229.58820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
45 Del Re AC, Maisel N, Blodgett JC, Wilbourne P, Finney JW. Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time. J Clin Psychopharmacol 2013;33:649-57. [PMID: 23857312 DOI: 10.1097/JCP.0b013e3182983e73] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
46 Stotts AL, Dodrill CL, Kosten TR. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009;10:1727-1740. [PMID: 19538000 DOI: 10.1517/14656560903037168] [Cited by in Crossref: 139] [Cited by in F6Publishing: 127] [Article Influence: 10.7] [Reference Citation Analysis]
47 Knox J, Hasin DS, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry 2019;6:1054-67. [PMID: 31630982 DOI: 10.1016/S2215-0366(19)30213-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
48 Malone M, McDonald R, Vittitow A, Chen J, Obi R, Schatz D, Tofighi B, Garment A, Kermack A, Goldfeld K, Gold H, Laska E, Rotrosen J, Lee JD. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemp Clin Trials 2019;81:102-9. [PMID: 30986535 DOI: 10.1016/j.cct.2019.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56. [PMID: 17880925 DOI: 10.1016/j.bcp.2007.08.005] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 11.0] [Reference Citation Analysis]
50 Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs 2006;66:1741-51. [PMID: 16978037 DOI: 10.2165/00003495-200666130-00006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]